Skip to main content

Table 3 Change from baseline and treatment differences in WOMAC™ total and subscale scores at study end

From: First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

  WOMAC™ total score WOMAC™ pain subscale score WOMAC™ DPDA subscale scorea WOMAC™ stiffness subscale score
Change from baseline at study end (mean ± SD)
   Lumiracoxib 400 mg daily (n = 144) -21.3 ± 19.9 -4.4 ± 4.4 -15.4 ± 14.6 -1.5 ± 1.9
   Celecoxib 200 mg twice daily (n = 145) -17.6 ± 14.2 -4.0 ± 3.3 -12.3 ± 10.5 -1.3 ± 1.8
   Placebo (n = 75) -12.5 ± 13.4 -2.7 ± 3.2 -9.0 ± 9.8 -0.8 ± 1.5
Estimated treatment differences at study end (least square means [95% CI])
   Lumiracoxib versus placebo -8.9 (-13.30 to -4.56)*** -1.8 (-2.77 to -0.83)*** -6.4 (-9.62 to -3.23)*** -0.7 (-1.14 to -0.31)***
   Celecoxib versus placebo -4.8 (-9.15 to -0.44)* -1.1 (-2.02 to -0.10)* -3.1(-6.30 to +0.07) -0.6 (-1.00 to -0.18)**
   Lumiracoxib versus celecoxib -4.1 (-7.76 to -0.51)* -0.7 (-1.54 to +0.06) -3.3 (-5.96 to -0.66)* -0.1 (-0.47 to +0.21)
  1. aData missing for one patient in each of the lumiracoxib and celecoxib treatment groups. *P < 0.05, **P < 0.01, ***P = 0.001. CI, confidence interval; DPDA, difficulty in performing daily activities; SD, standard deviation; WOMAC™ = Western Ontario and McMaster Universities Osteoarthritis Index.